Incyte partners with Enable Injections for drug delivery system
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Incyte (INCY) PT Raised to $109 at BofA Securities
October 28, 2025 10:31 AM EDTBofA Securities analyst Tazeen Ahmad raised the price target on Incyte (NASDAQ: INCY) to $109.00 (from $104.00) while maintaining a Buy rating.
The analyst comments "Incyte (INCY) reported 3Q revenues for Jakafi of $791mn (+2% q/q, ours: $774mn, cons: $773mn), Opzelura of $188mn (+6% q/q, our:... More
